Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
pubmed:
24
10
2020
medline:
5
1
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response. 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response. The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort. In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile. MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.
Identifiants
pubmed: 33095670
doi: 10.1259/bjr.20200696
pmc: PMC7774684
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20200696Références
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Br J Radiol. 2016 Dec;89(1068):20160348
pubmed: 27748126
Radiother Oncol. 2007 May;83(2):163-7
pubmed: 17499871
Radiother Oncol. 2016 Jan;118(1):112-7
pubmed: 26796591
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e377-83
pubmed: 21514068
Radiother Oncol. 2013 Nov;109(2):217-21
pubmed: 24060175
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):361-373
pubmed: 29353654
Radiat Oncol. 2013 May 13;8:118
pubmed: 23668632
Cureus. 2015 Dec 04;7(12):e395
pubmed: 26798571
JAMA. 2015 Sep 22-29;314(12):1291-3
pubmed: 26393854
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50
pubmed: 16198506
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Radiother Oncol. 2006 Dec;81(3):284-90
pubmed: 17125866
Acta Oncol. 2012 Nov;51(8):963-74
pubmed: 22966812
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):473-480
pubmed: 28463167
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105
pubmed: 12128107
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):909-14
pubmed: 20732764
J Clin Oncol. 2006 May 1;24(13):1990-6
pubmed: 16648499
Cureus. 2019 Dec 24;11(12):e6457
pubmed: 32025388
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Radiat Oncol. 2020 Mar 23;15(1):69
pubmed: 32248826
Lancet Oncol. 2019 Nov;20(11):1531-1543
pubmed: 31540791
Radiat Oncol. 2011 Jan 10;6:3
pubmed: 21219625
J Clin Oncol. 2015 Feb 1;33(4):332-9
pubmed: 25534388
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1013-21
pubmed: 20447774
Front Oncol. 2015 Jan 22;4:369
pubmed: 25657929
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):339-44
pubmed: 24411606
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):161-170
pubmed: 27780694
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1086-1094
pubmed: 31419510
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):587-94
pubmed: 16690440
JAMA Netw Open. 2019 Feb 1;2(2):e188006
pubmed: 30735235
Lancet Oncol. 2007 Jun;8(6):475-87
pubmed: 17482880
Pract Radiat Oncol. 2021 Jan-Feb;11(1):e11-e21
pubmed: 32739438
J Clin Oncol. 2018 Oct 11;:JCO1801097
pubmed: 30307776
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Radiat Oncol. 2017 Sep 7;12(1):149
pubmed: 28882187